| __timestamp | Bio-Techne Corporation | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 22570000 |
| Thursday, January 1, 2015 | 119401000 | 24378000 |
| Friday, January 1, 2016 | 140879000 | 26621000 |
| Sunday, January 1, 2017 | 199243000 | 28653000 |
| Monday, January 1, 2018 | 240636000 | 37734000 |
| Tuesday, January 1, 2019 | 264359000 | 41884000 |
| Wednesday, January 1, 2020 | 260583000 | 64435000 |
| Friday, January 1, 2021 | 324951000 | 57483000 |
| Saturday, January 1, 2022 | 372766000 | 70062000 |
| Sunday, January 1, 2023 | 378378000 | 52790000 |
| Monday, January 1, 2024 | 396826000 |
Cracking the code
In the dynamic world of biotechnology, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial for evaluating company performance. Over the past decade, Bio-Techne Corporation has consistently outpaced Ligand Pharmaceuticals Incorporated in SG&A spending, reflecting a strategic focus on growth and market expansion. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, peaking at nearly $400 million in 2023. In contrast, Ligand Pharmaceuticals showed a more modest increase of approximately 130% over the same period, with expenses reaching around $70 million in 2022. This disparity highlights Bio-Techne's aggressive investment in administrative capabilities and market presence. However, the absence of data for Ligand in 2024 suggests a potential shift or reevaluation in their financial strategy. As the biotech landscape evolves, these insights offer a window into the strategic priorities of leading firms.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Merck & Co., Inc. vs Ligand Pharmaceuticals Incorporated
Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: MorphoSys AG vs Ligand Pharmaceuticals Incorporated Trends and Insights
Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared